Low vitamin B6 levels predict worse outcomes in primary sclerosing cholangitis patients across multiple countries, according to research reviewed by Gram Research. A study of 1,220 PSC patients from Norway, the U.S., and Germany found that those with vitamin B6 deficiency were significantly more likely to need liver transplants, die from their disease, or develop serious liver complications. About 50% of Norwegian and 25% of American PSC patients had vitamin B6 deficiency, and vitamin B6 levels added useful predictive information beyond existing disease severity measures.
Researchers studied vitamin B6 levels in people with primary sclerosing cholangitis (PSC), a serious liver disease that damages bile ducts. According to Gram Research analysis, they found that people with low vitamin B6 had worse health outcomes across three countries—Norway, the U.S., and Germany. About half of Norwegian patients and a quarter of American patients had vitamin B6 deficiency. The study shows that checking vitamin B6 levels could help doctors predict which patients might get sicker faster and need a liver transplant sooner. This discovery could help doctors better care for PSC patients by identifying and treating vitamin B6 deficiency early.
Key Statistics
A 2026 study of 1,220 primary sclerosing cholangitis patients across Norway, the U.S., and Germany found that 50% of Norwegian and 25% of American patients had vitamin B6 deficiency, with low vitamin B6 consistently predicting worse outcomes including liver transplant need and death.
Research published in the Journal of Hepatology showed that vitamin B6 deficiency was more common in PSC patients who had already experienced hepatic decompensation (serious liver failure), suggesting vitamin B6 levels may help identify high-risk patients.
A multi-country analysis of 1,220 PSC patients found that vitamin B6 levels added predictive value for transplant-free survival beyond contemporary prediction models, meaning doctors could better forecast disease progression by checking vitamin B6 levels.
The Quick Take
- What they studied: Whether low vitamin B6 levels predict worse outcomes in people with primary sclerosing cholangitis (a disease where the bile ducts in the liver get damaged and scarred)
- Who participated: 1,220 patients with PSC from three countries: 315 from Norway, 756 from the U.S., and 149 from Germany. Researchers looked at their vitamin B6 blood levels and tracked their health over time.
- Key finding: People with low vitamin B6 were significantly more likely to need a liver transplant or die from their disease, and they were also more likely to develop serious liver complications. This pattern held true across all three countries studied.
- What it means for you: If you have PSC, getting your vitamin B6 levels checked could help your doctor predict your disease course and catch problems early. However, this research doesn’t yet prove that taking vitamin B6 supplements will improve outcomes—more studies are needed to test that.
The Research Details
Researchers looked back at medical records from PSC patients in Norway, the U.S., and Germany. They measured vitamin B6 levels in blood samples using a precise lab technique called LC-MS/MS. They then followed patients over time to see who needed liver transplants, who died, and who developed serious liver complications like hepatic decompensation (when the liver stops working properly). The researchers used statistical models to figure out whether low vitamin B6 predicted these bad outcomes, even when accounting for other factors that affect disease severity.
This type of study is called a retrospective cohort study, which means researchers looked backward at existing patient data rather than randomly assigning people to different treatments. The study included patients from three different countries, which helps show whether the findings apply broadly or just in one place.
The researchers defined vitamin B6 deficiency as levels below 20 nmol/L (a measurement unit for blood concentration). They looked at how vitamin B6 levels compared to outcomes and whether vitamin B6 added useful information beyond what doctors already use to predict PSC outcomes.
Understanding what predicts worse outcomes in PSC is important because the disease progresses differently in different people. Some patients stay stable for years, while others get much sicker quickly. If doctors can identify which patients are at highest risk using a simple blood test, they can plan transplants better and monitor high-risk patients more closely. Testing this in three different countries also shows whether findings from one region apply everywhere, which makes the results more trustworthy for doctors worldwide.
This study is strong because it included over 1,200 patients from three different countries, making the results more likely to apply broadly. The researchers used precise lab methods to measure vitamin B6. However, because this was a retrospective study looking at past records, researchers couldn’t control all the factors that might affect outcomes. The study shows that low vitamin B6 is associated with worse outcomes, but it doesn’t prove that vitamin B6 deficiency causes the worse outcomes—other factors could be involved. The study was published in a top liver disease journal, which suggests it passed rigorous scientific review.
What the Results Show
Low vitamin B6 levels consistently predicted worse outcomes across all three countries. In the Norwegian group, 50% of patients had vitamin B6 deficiency, while in the U.S. group, 25% had deficiency. Patients with low vitamin B6 were significantly more likely to need a liver transplant or die from PSC compared to those with normal vitamin B6 levels. The risk of bad outcomes increased sharply as vitamin B6 levels dropped into the deficiency range, but the risk leveled off once vitamin B6 was at normal levels.
The study also found that low vitamin B6 predicted the development of hepatic decompensation—a serious condition where the liver stops working properly. This was especially noticeable in the U.S. group, where liver decompensation was more common overall. Importantly, vitamin B6 levels added useful predictive information beyond what doctors already use to estimate PSC outcomes, meaning it could help doctors make better predictions about which patients will get sicker.
Patients who had already experienced liver decompensation were more likely to have low vitamin B6, suggesting that vitamin B6 deficiency might be both a marker of disease severity and possibly a consequence of advanced liver disease. The relationship between vitamin B6 and outcomes was similar across all three countries, even though the countries had different healthcare systems and treatment approaches.
The study found differences between countries in how PSC progressed. In Norway, patients were more commonly transplanted for reasons other than hepatic decompensation, while in the U.S., liver decompensation was a more common reason for transplant. Despite these differences in disease patterns, the relationship between low vitamin B6 and poor outcomes remained consistent. The study also showed that vitamin B6 deficiency was common in PSC patients outside of Scandinavia, suggesting this is a widespread problem affecting PSC patients globally.
This research builds on earlier studies from Scandinavia that first showed vitamin B6 deficiency predicted worse outcomes in PSC. The current study validates those findings in a much larger U.S. population and adds new information about vitamin B6’s connection to hepatic decompensation. By studying three countries with different healthcare systems, the researchers showed that the vitamin B6-outcome relationship isn’t unique to Scandinavia but appears to be a universal pattern in PSC. This makes the findings more important for doctors worldwide.
This study looked backward at existing medical records rather than randomly assigning patients to different vitamin B6 levels, so it can’t prove that low vitamin B6 causes worse outcomes—only that they’re connected. The study didn’t measure other factors that might affect both vitamin B6 levels and disease outcomes, such as diet, alcohol use, or other nutritional deficiencies. The three countries had different healthcare systems and treatment practices, which might have affected results. The study doesn’t tell us whether giving vitamin B6 supplements to deficient patients would actually improve outcomes—that would require a different type of study where some patients receive supplements and others don’t.
The Bottom Line
If you have PSC, ask your doctor to check your vitamin B6 levels. If you’re deficient, work with your doctor to address it, though the evidence for supplements isn’t yet proven. Doctors should consider vitamin B6 levels when predicting which PSC patients are at highest risk for complications. However, vitamin B6 testing should be used alongside existing prediction tools, not instead of them. (Confidence: Moderate—the association is strong and consistent, but we don’t yet know if treating deficiency improves outcomes.)
This research is most relevant for people with primary sclerosing cholangitis and their doctors. It may also be relevant for liver specialists who manage PSC patients. General readers without PSC don’t need to change their vitamin B6 intake based on this study. People with other liver diseases should not assume these findings apply to them.
If vitamin B6 deficiency is identified and treated, improvements in disease outcomes would likely take months to years to become apparent, since PSC progresses slowly. This isn’t a quick fix but rather a long-term management strategy.
Frequently Asked Questions
What is primary sclerosing cholangitis and why does vitamin B6 matter for this disease?
Primary sclerosing cholangitis (PSC) is a disease where bile ducts in the liver become scarred and damaged, eventually leading to liver failure. Research shows low vitamin B6 predicts worse outcomes in PSC patients, including faster disease progression and need for transplant. Checking vitamin B6 levels helps doctors identify high-risk patients.
How common is vitamin B6 deficiency in people with PSC?
According to a 2026 study of 1,220 PSC patients, vitamin B6 deficiency affected about 50% of Norwegian patients and 25% of American patients. Deficiency was even more common in patients who had already experienced serious liver complications, suggesting it’s a widespread problem in PSC.
If I have PSC and low vitamin B6, will taking supplements help my liver disease?
This study shows low vitamin B6 is associated with worse PSC outcomes, but it doesn’t prove that supplements will improve outcomes. You should discuss vitamin B6 testing and management with your liver specialist, who can recommend whether supplementation is appropriate for your situation.
Does this vitamin B6 finding apply to people with other liver diseases?
This research specifically studied primary sclerosing cholangitis patients. The findings may not apply to other liver diseases. If you have a different liver condition, ask your doctor whether vitamin B6 levels are relevant to your care.
How often should PSC patients get their vitamin B6 levels checked?
The study doesn’t specify testing frequency, so discuss this with your liver specialist. They may recommend annual or semi-annual testing, especially if you’ve had low vitamin B6 before or if you’ve experienced liver complications. Regular monitoring helps track whether your vitamin B6 status is improving.
Want to Apply This Research?
- If you have PSC and your doctor has checked your vitamin B6 levels, track your vitamin B6 test results and dates in the app. Record the actual blood level number (measured in nmol/L) and note whether your doctor classified it as deficient, marginal, or sufficient. Set reminders for annual or semi-annual vitamin B6 testing.
- Work with your doctor to develop a vitamin B6 management plan. This might include dietary changes (eating more vitamin B6-rich foods like chickpeas, salmon, and potatoes) or, if recommended by your doctor, supplementation. Use the app to track whether you’re following the plan and to log any dietary sources of vitamin B6 you consume.
- Create a long-term tracking dashboard showing your vitamin B6 test results over time, your PSC symptoms or complications, and any treatments you’re using. Share this data with your liver specialist at each visit to help them monitor your disease progression and adjust your management plan.
This article summarizes research about vitamin B6 and primary sclerosing cholangitis but is not medical advice. If you have PSC or any liver disease, consult your hepatologist or liver specialist before making changes to your vitamin B6 intake or supplementation. This study shows an association between low vitamin B6 and worse outcomes but does not prove that vitamin B6 supplementation will improve your health. Do not use this information to self-diagnose or self-treat. Always work with your healthcare provider to develop an appropriate management plan for your specific condition.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.